1Kaufman DB,Shapiro R,Lucey MR,et al.Immunosuppression:practice and trends.Am J Transplant,2004,4(suppl 1):S38-S53.
2Halloran PF.Immunosuppressive drugs for kidney transplantation.N Engl J Med,2004,351(26):2715-2729.
3van Gelder T,Hilbrands LB,Vanrenterghem Y,et al.A randomized double-blind,multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.Transplant,1999,68(2):261-266.
4Oellerich M,Shipkova M,Schutz E,et al.Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation:implications for therapeutic drug monitoring.Ther Drug Monit,2000,22(1):20-26.
5Mourad M,Malaise J,Chaib ED,et al.Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treatedwithmycophenolate mofetil.Clin Chem,2001,47(1):88-94.
6Johnston A,Holt DW.Immunosuppressant drugs-role of therapeutic drug monitoring.Br J Clin Pharmacol,2001,52(suppl Ⅰ):S61-S73.
7Bullingham IRES,Nicholls A,Hale M.Pharmacokinetics of mycophenolate mofetil(RS61443):8 short review.Transplant Proc,1996,28(2):925-929.
8Shaw LM,Korecka M,DeNofrio D,et al.Pharmacokinetic,pharmacodynamic,and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.Clin Biochem,2001,34(1):17-22.
9Wong SHY.Therapeutic drug monitoring for immunosuppressants.Clin Chim Acts,2001,313(1-2):241-253.
10Mardigyan V,Chervenkov J,Etrakos P,et al.Best Single Time Points as Surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.Chem herapeutic,2005,27(4):463-469.
7DIN M,CARLO S C,MAGNI M,et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J].Blood,2002,99(10):3838-3843.
8HORWITS E M,LE B K,DOMINICI M,et al.The international society for cellular therapy:clarification of the nomenclature for MSC:the international society for cellular position statement[J].Cytotheaty,2005,7(5):393-395.
9LE B K,FRASSONI F,BALL L,et al.On behalf of the Developmental Committee of the European Group for Blood and Marrow Transplantation:mesenchymal stem cells for treatment of steroid-resistant,severe,acute graft-versus-host desease:a phaseⅡstudy[J].Lancet,2008,371(9624):1579-1586.
10HEMATTI P.Role of mesenchymal stromal cells in solid organ transplantation[J].Transplant Rev,2008,22(4):262-273.
